1. Daewoong Pharmaceutical’s Q2 2025 Performance: What Happened?

On August 14, 2025, Daewoong Pharmaceutical announced its Q2 2025 preliminary earnings. Revenue reached ₩405.4 billion, operating profit ₩57.8 billion, and net income ₩40.1 billion. This represents a year-on-year increase of 5%, 12%, and 7% respectively, surpassing market forecasts.

2. Behind the Strong Performance: Key Growth Drivers

This strong performance is attributed to robust domestic and international sales of key products and efficient cost management. The high export ratio of specific products demonstrates Daewoong’s global competitiveness. Furthermore, the company has secured future growth drivers, including new overseas export contracts and a joint development agreement for depot injections. The rise in the KRW/USD exchange rate also positively impacted Daewoong’s export business.

3. Investment Strategy: What’s Next?

While Daewoong’s future looks promising, investors should remain aware of certain factors. The success of new drug pipeline development and external factors like exchange rate fluctuations require continuous monitoring. Key considerations for investors include:

  • Monitoring new drug pipeline and export contracts
  • Managing exchange rate and interest rate volatility
  • Analyzing market share and competitive landscape for key products
  • Assessing improvements in financial health (debt ratio, ROE)